China Resources Pharma, China’s second largest drug company and a subsidiary of state-owned China Resources, is planning an IPO in Hong Kong that will raise at least $1 billion; Hutchison China MediTech filed a third iteration of a prospectus for its $100 million US IPO, which is still not final; Pharmaron, a Beijing CRO/CMO, acquired Quotient Bioresearch of the UK and its radiochemistry expertise; Xizang Haisco Pharma led a $15 million Series D funding for Regentis Biomaterials, an Israeli medical device company, and will market Regentis’ cartilage regeneration device in China; Shanghai Golden Grand-Medical Instruments will begin a China trial of a minimally invasive device developed by Medigus of Israel to treat GERD; and Lianshan Zhang, PhD, President of Global R&D at Hengrui Medicine spoke in an exclusive interview with ChinaBio® Today about Hengrui’s historic $795 million out-licensing of its PD-1 molecule to Incyte of the US. 

Stock Symbols: (AIM: HCM) (SHZ: 002653)